Literature DB >> 23059764

Immunotherapeutic strategies for cancer treatment: a novel protein transfer approach for cancer vaccine development.

Rangaiah Shashidharamurthy1, Erica N Bozeman, Jaina Patel, Ramneet Kaur, Jeyandra Meganathan, Periasamy Selvaraj.   

Abstract

Cancer cells have developed numerous ways to escape immune surveillance and gain unlimited proliferative capacity. Currently, several chemotherapeutic agents and radiotherapy, either alone or in combination, are being used to treat malignancies. However, both of these therapies are associated with several limitations and detrimental side effects. Therefore, recent scientific investigations suggest that immunotherapy is among the most promising new approaches in modern cancer therapy. The focus of cancer immunotherapy is to boost both acquired and innate immunity against malignancies by specifically targeting tumor cells, and leaving healthy cells and tissues unharmed. Cellular, cytokine, gene, and monoclonal antibody therapies have progressively become promising immunotherapeutic approaches that are being tested for several cancers in preclinical models as well as in the clinic. In this review, we discuss recent advances in these immunotherapeutic approaches, focusing on new strategies that allow the expression of specific immunostimulatory molecules on the surface of tumor cells to induce robust antitumor immunity.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 23059764     DOI: 10.1002/med.20237

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  8 in total

1.  Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.

Authors:  Jaina M Patel; Vincent F Vartabedian; Min-Chul Kim; Sara He; Sang-Moo Kang; Periasamy Selvaraj
Journal:  Biotechnol Bioeng       Date:  2015-04-17       Impact factor: 4.530

2.  Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12.

Authors:  Kun Tao; Ya-Juan Li; Dong Wang; Jie-Yu Qi; Yi-Ping Deng; Hai-Xia Wang; Jing Hu; Wen-Li Feng
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

Review 3.  Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.

Authors:  Stephen Brimijoin; Xiaoyun Shen; Frank Orson; Thomas Kosten
Journal:  Expert Rev Vaccines       Date:  2013-03       Impact factor: 5.217

4.  Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.

Authors:  A B Del Campo; J Carretero; J A Muñoz; S Zinchenko; F Ruiz-Cabello; G González-Aseguinolaza; F Garrido; N Aptsiauri
Journal:  Cancer Gene Ther       Date:  2014-06-27       Impact factor: 5.987

5.  Stapling strategy enables improvement of antitumor activity and proteolytic stability of host-defense peptide hymenochirin-1B.

Authors:  Yulei Li; Minghao Wu; Qi Chang; Xia Zhao
Journal:  RSC Adv       Date:  2018-06-19       Impact factor: 3.361

6.  Nanomaterials in the application of tumor vaccines: advantages and disadvantages.

Authors:  Xd Li; Jy Gao; Y Yang; Hy Fang; Yj Han; Xm Wang; W Ge
Journal:  Onco Targets Ther       Date:  2013-06-05       Impact factor: 4.147

Review 7.  Biomedical applications of glycosylphosphatidylinositol-anchored proteins.

Authors:  Susanne Heider; John A Dangerfield; Christoph Metzner
Journal:  J Lipid Res       Date:  2016-08-19       Impact factor: 5.922

8.  Virus like particles as a platform for cancer vaccine development.

Authors:  Hui Kian Ong; Wen Siang Tan; Kok Lian Ho
Journal:  PeerJ       Date:  2017-11-15       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.